Catherine M. Gordon

ORCID: 0000-0002-9280-9143 · 15 papers in corpus
other 2025
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2025.03.005

STUDY OBJECTIVE: Estrogen replacement therapy (ERT) improves bone and neurocognitive health in adult women with premature ovarian insufficiency (POI). However, the response in adolescents is largely unknown. We aimed to assess the impact of…

other 2022
JAMA network open ·doi:10.1001/jamanetworkopen.2022.39763
review 2021
Frontiers in reproductive health ·doi:10.3389/frph.2021.670919

Awareness and visibility of transgender individuals have grown exponentially. However, conceptualizing sexual and reproductive health (SRH) as "women's" or "men's" health services further marginalizes transgender and gender-expansive (TGE) …

case-report 2021
Journal of the Endocrine Society ·doi:10.1210/jendso/bvab098

INTRODUCTION: GNAS mutations have been reported in both McCune-Albright syndrome (MAS) and juvenile granulosa cell tumors (JGCT) but have never been reported simultaneously in the same patient. CASE PRESENTATION: A 15-year-old girl develop…

2018
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2018.02.074
rct 2018
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2018.03.004

STUDY OBJECTIVE: To explore the potential occurrence of long-term side effects and tolerability of gonadotropin-releasing hormone agonist (GnRHa) plus 2 different add-back regimens in adolescent patients with endometriosis. DESIGN: Follow-…

rct 2016
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2016.02.008

STUDY OBJECTIVE: Use of gonadotropin-releasing hormone agonists (GnRHa) to treat endometriosis can cause mood and vasomotor side effects. "Add-back therapy," the combination of low-dose hormones, limits side effects but research is limited …

2015
·doi:10.1016/j.jadohealth.2014.10.049
rct 2015
·doi:10.1097/ogx.0000000000000249

Endometriosis often begins during adolescence. Appropriate management includes prompt initiation of therapy and long-term maintenance therapy. Gonadotropin-releasing hormone (GnRH) agonists are commonly used second-line therapy for patients…

rct 2015
Obstetrics and gynecology ·doi:10.1097/aog.0000000000000964

OBJECTIVE: To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agoni…

2015
·doi:10.1016/j.jpag.2015.02.008
review 2011
Pediatrics ·doi:10.1542/peds.2010-2221

Heightened publicity about hormonal contraception and thrombosis risk and the publication of new guidelines by the World Health Organization in 2009 and the Centers for Disease Control and Prevention in 2010 addressing this complex issue ha…

observational 2007
Journal of Pediatric and Adolescent Gynecology ·doi:10.1016/j.jpag.2007.04.008

STUDY OBJECTIVE: To evaluate the bone density of adolescents with endometriosis treated with a GnRH-agonist and "add-back" therapy with norethindrone acetate. DESIGN: Retrospective chart review. SETTING: Pediatric gynecology clinic at a t…

2006
·doi:10.1016/j.jpag.2006.01.021
review 1998
The Journal of reproductive medicine

OBJECTIVE: To review the impact of gonadotropin-releasing hormone agonists (GnRH-as) on bone mass in adolescents and options for GnRH-a with "add-back" for long-term therapy for adolescents with endometriosis not responding to conventional …